|
|
|
|
|
市場調査レポート
医薬品業界におけるビジネスインテリジェンス（BI）の機会評価
Evaluating Business Intelligence Opportunities in the Pharmaceutical Industry (Strategy Focus)
|
当商品の販売は、2011年07月19日を持ちまして終了しました。
Abstract
Overview
Introduction
As market pressures demand increased innovation and shorter time-to-market
product lifecycles, pharmaceutical companies are evaluating alternative
business models, focusing on technologies - such as business intelligence (BI)
tools -for translational medicine.
Scope
- Examines essential ingredients of sales strategies for BI vendors serving
the pharmaceutical industry
- Identifies strategies vendors should use to develop more effective
relationships and drive solution sales
- Offers profiles of leading vendors selling BI tools to the Big Pharma and
Biotech market
Report Highlights
Market factors are driving adoption of translational research and specifically
BI solutions
BI opportunities exist at several levels within the pharmaceutical market
BI vendors with high market readiness will realize the most success in the
pharmaceutical industry
Reasons to Purchase
- Understand how to evaluate market opportunities for BI solutions in the
pharmaceutical market
- Discover new ways to leverage relationships as a tool to drive market
penetration
- Gain insight into Datamonitor' s perspective on what makes a vendor
successful
Table of Contents
- DATAMONITOR VIEW
- CATALYST
- SUMMARY
- METHODOLOGY
- ANALYSIS
- Market factors are driving adoption of translational medicine and
specifically BI solutions
- External pressures are driving pharmaceutical companies to embrace
translational research
- Both cultural and technology barriers slow the progress of
translational medicine
- BI opportunities exist at several levels within the pharmaceutical market
- Enterprise-class BI solutions have the power to evolve with an
organization' s changing business needs
- BI spending by end-user group in Big Pharma and Biotech differs
significantly
- The industry requires vendors with high "market readiness" in
translational medicine
- Market sizing information is necessary but insufficient for
identifying which sector to target
- Vendors should consider four criteria when evaluating market
opportunities
- Market presence influences client perception about a BI solution and
its vendor
- Industry-specific solutions reflect domain expertise
- A sales force with industry experience will resonate with
pharmaceutical clients
- Partnerships with niche vendors or academic medical centers (AMCs)
build credibility
- BI vendors with high market readiness will realize the most success in
the pharmaceutical industry
- A number of vendors have implemented successful strategies for BI in
pharmaceuticals
- Genstruct
- GenoLogics Life Sciences Software Inc. (GenoLogics)
- Oracle
- SAS
- ACTIONS
- BI solutions for Biotech and Big Pharma are not "one size fits...both"
- Approach an attaractive opportunity through the market-readiness lens
- Partner with innovators
- APPENDIX
- Definitions
- Abbreviations
- Further reading
- Datamonitor Technology Consultancy
- Ask the analyst
- List of Figures
- Figure 1: The Big Pharma sector is the largest market opportunity in
BI solutions ($ spent)
- Figure 2: BI spending by technology (services vs. software) 2006-2012
- Figure 3: Big Pharma will spend more on BI tools for clinical and
sales & marketing application than Biotech
- Figure 4: A framework for evaluating BI market opportunities in the
pharmaceutical industry
- Figure 5: Both horizontal and niche vendors offer valuable BI
solutions for translational medicine
|
 |
